BT Global Growth Monthly Report Paul Beattie is a very successful fund manager at BT Global and has an investment in MedX according to his recent Monthly Reports.
Here are his comments on MedX this month.
A more striking comparable is the MedX Health Corp (MDX.v), with a market cap of C $40 mil. which will be bringing tele-dermatology to the world using special cameras and digitizing pictures of skin abnormalities. The US comparable is DermTech (DMTK) with a market cap of US $1.8 bil. and revenues of $5 mil. These are small indications of the value gap between our two countries’ equity markets. We are not claiming that these companies should trade at similar values, but simply pointing out the massive valuation discrepancies and the likelihood that the Canadian names will get US investor buying interest at one point, partially closing the gap.